Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Calquence 100 mg Capsules General Drug Use-Results Study; All Patient Investigation in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)

NCT04872621 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04872621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04872621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Calquence 100 mg Capsules General Drug Use-Results Study; All Patient Investigation in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
June 30, 2021
Completion date
September 4, 2024
Enrollment
104 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)